Search results for "Phoma"

showing 10 items of 716 documents

Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for auto…

2007

A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 (90Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII…

Malemedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentImmunologyIbritumomab tiuxetanSalvage therapyAuthor Keywords:RadioimmunotherapyBiochemistryGastroenterologyAntibodies Monoclonal Murine-DerivedTRIAL Author InformationAutologous stem-cell transplantationRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineRefractory Diffuse Large B-Cell LymphomaHumansYttrium RadioisotopesY-90-ibritumomab tiuxetanHematologic toxicity KeyWords Plus:B-CELL LYMPHOMAAuthor Keywords:Radioimmunotherapy; Y-90-ibritumomab tiuxetan; Hematologic toxicity KeyWords Plus:B-CELL LYMPHOMA; LOW-GRADE; RADIOIMMUNOTHERAPY; INDOLENT; TRIAL Author InformationAgedCerebral HemorrhageAged 80 and overSalvage TherapyChemotherapybusiness.industryRemission InductionAntibodies MonoclonalCell BiologyHematologyRADIOIMMUNOTHERAPYINDOLENTmedicine.diseaseSurvival AnalysisLOW-GRADESurgeryTransplantationRituximabFemaleLymphoma Large B-Cell DiffusebusinessRituximabDiffuse large B-cell lymphomamedicine.drug
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct

Survival of Mycosis Fungoides in Patients in the Southeast of England

2004

<i>Background:</i> Mycosis fungoides (MF) is the most common skin lymphoma. The aetiology of MF remains unknown, and no therapy has to date significantly altered patient survival. <i>Objective:</i> The present study examines trends in survival of MF patients in a well-defined population-based disease group, namely patients registered over a 40-year period at the Thames Cancer Registry, Southeast England. <i>Methods:</i> The Thames Cancer Registry is a population-based registry, covering a population of approximately 14 million people. Data were taken from the Surveillance, Epidemiology and End Results cancer registry programme and the National Centre for …

Malemedicine.medical_specialtyPathologySkin NeoplasmsAntineoplastic Agents HormonalDermatologyCohort StudiesMycosis FungoidesSex FactorsResidence CharacteristicsEpidemiologymedicineHumansSezary SyndromeIn patientRegistriesSurvival rateAgedProportional Hazards ModelsMycosis fungoidesbusiness.industryProportional hazards modelAge FactorsMiddle AgedPrognosismedicine.diseaseDermatologyPeripheral T-cell lymphomaLymphomaSurvival RateEnglandPopulation SurveillanceEtiologyFemalebusinessFollow-Up StudiesSEER Program
researchProduct

Linfomas malignos primários nas glandulas salivares

2011

Primary malignant lymphomas in the salivary glands are relatively rare. Clinical presentation is not characteristic and the disease is often overlooked resulting in diagnosis and treatment delays. AIM: To stress the importance of the diagnostic process and combined management, we present a series of eight patients with malignant lymphoma of the parotid who were diagnosed only after surgery and managed with radiation and chemotherapy. METHODS: Retrospective series of patients with primary malignant lymphoma of the parotid gland managed with radiotherapy and diagnostic surgical partial resection. RESULTS: After treatment completion we achieved a loco-regional control rate of 87.5%. Toxicity w…

Malemedicine.medical_specialtyPathologyglândulas salivaresSettore MED/06 - Oncologia Medicamedicine.medical_treatmentsalivary glandsSettore MED/19 - Chirurgia PlasticalymphomaDiseaseradioterapiaSettore MED/29 - Chirurgia Maxillofaccialestomatognathic systemlymphoma parotid salivary gland non-Hodgkin surgeryHumansMedicineStage (cooking)linfomalinfoma não hodgkinradiotherapyneoplasias parotídeasAgedRetrospective StudiesAged 80 and overPharmacologyChemotherapybusiness.industryLymphoma Non-HodgkinRate controlMiddle AgedPartial resectionmedicine.diseaseCombined Modality Therapynon-hodgkinLymphomaParotid glandRadiation therapyparotid neoplasmsTreatment Outcomemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaFemaleRadiologybusiness
researchProduct

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment

2004

Primary hepatic lymphoma is a rare but well-defined lymphoma entity that often pursues an aggressive clinical course. Most cases have been described in hepatitis C virus (HCV)-related chronic liver disease patients. Although anthracycline-based chemotherapy has been reported to be highly effective, the best therapeutic strategy has not been defined yet. The prognosis is dismal especially in patients treated with chemotherapy alone or when an advanced liver disease is present. Herein, we describe a case of primary hepatic large B-cell non-Hodgkin’s lymphoma, in a patient with HCV chronic infection. After a minor response with eight cycles of CHOP chemotherapy, a complete and sustained remiss…

Malemedicine.medical_specialtyalpha-interferonHepatitis C virusAlpha interferonCHOPChronic liver diseasemedicine.disease_causeGastroenterologyLiver diseasehemic and lymphatic diseasesInternal medicineremission primary hepatic lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicinevirus infectionHumansUltrasonographyHematologybusiness.industryLymphoma Non-HodgkinLiver NeoplasmsRemission InductionInterferon-alphaHematologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLymphomaLong-lastingImmunologyLymphoma Large B-Cell Diffusehepatitis Cbusiness
researchProduct

Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors

2018

Vitamin D (25-OHD) has a role in bone health after treatment for cancer. 25-OHD deficiency has been associated with risk factors for cardiovascular disease, but no data focusing on this topic in childhood cancer survivors have been published. We investigated the 25-OHD status in children treated for acute lymphoblastic leukemia (ALL), and evaluated its influence on vascular function. 25-OHD levels were evaluated in 52 ALL survivors and 40 matched healthy controls. Patients were grouped according to 25-OHD level (< 20 ng/m or ≥ 20 ng/ml). Auxological parameters, biochemical and hemostatic markers of endothelial function (AD, HMW-AD, ET-1, vWFAg, TAT, D-dimers, Fbg, and hs-CRP), ultrasound ma…

Malemedicine.medical_specialtyendocrine system diseasesAdolescentDiseaseAcute lymphoblastic leukemiaurologic and male genital diseasesGastroenterologyC-IMT03 medical and health sciencesYoung Adult0302 clinical medicineRisk Factors030225 pediatricsmedicine.arteryInternal medicinePediatric surgerymedicineVitamin D and neurologyHumans030212 general & internal medicineSurvivorsVitamin DChildChildhood Acute Lymphoblastic LeukemiaUnivariate analysisbusiness.industryAbdominal aortaConfoundingnutritional and metabolic diseasesCancerPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVitamin D DeficiencyCardiovascular diseaseChild PreschoolPediatrics Perinatology and Child HealthFemaleEndothelium VascularbusinessBiomarkersVascular ultrasound studie
researchProduct

Cancer prevalence is increased in females with sleep apnoea: data from the ESADA study

2019

[No abstract available]

MaleobesityLetterDatabases FactualDownload[SDV]Life Sciences [q-bio]cigarette smokingPolysomnographycancer riskdisease burdenapnea hypopnea indexsleep disordered breathingstudy design0302 clinical medicinepolysomnographyRisk FactorsNothingcancer diagnosisNeoplasmsmiddle agedgenderPrevalence030212 general & internal medicineSleep studyobstructive sleep apneaSleep Apnea Obstructiveeducation.field_of_studyanthropometryquantitative analysismedicine.diagnostic_testadultrisk assessmentclinical trialcohort analysisprostate cancerpulse oximetry[SDV] Life Sciences [q-bio]Europenot availablecomorbidityagedfemalewaist hip ratiocolon cancerpriority journalrisk factorfactual databasedisease severitycerebrovascular accidentPulmonary and Respiratory Medicinemedicine.medical_specialtyalcohol consumptionintermittent hypoxiaPopulationMEDLINElymphomaSettore MED/10 - Malattie Dell'Apparato Respiratoriomalignant neoplasmcancer growth03 medical and health sciencesmelanomamedicinecancercross-sectional studyHumanscontrolled studyhumaneducationCancer prevalencehypoxiabusiness.industrystatistical modelConflict of interestpredictionmajor clinical studybody massoxygen saturationlung cancermulticenter studyCross-Sectional StudiesLogistic Modelsage030228 respiratory systemdisease severity assessmentFamily medicineoxygen desaturation indexhead and neck cancerHuman medicinebusinessneoplasmEuropean Respiratory Journal
researchProduct

Chromatic-achromatic perimetry in four clinic cases: Glaucoma and diabetes

2015

Color perimetry has interesting clinical application for the diagnosis and detection of certain eye conditions, due to the variations that certain diseases can cause in chromatic thresholds, both in the red-green (RG) and the blue-yellow (BY) pathways.[1,2,3,4] The separate study of the visual function of both the chromatic and achromatic mechanisms could be more efficient in detecting sensitivity variations, and such variations would not be obscured by the intrusion of other mechanisms. Currently, the supply of conventional perimeters that are capable of performing a chromatic perimetry test is very limited and with reduced options regarding the possibility of choosing the physical charact…

Maleretinakoniohemangioblastomagenetic structuresComputer sciencemelanocytosisGlaucomaretinal vasoproliferative tumorEyeTwo stageslaw.inventionintra-arterial chemotherapyretinal capillary hemangiomaIntrusionlcsh:Ophthalmologylawperiocular chemotherapyintravitreal chemotherapytreatmentdiabetesenhanced depth imagingDiabetesenhanced depth imaging optical coherence tomographyMiddle AgedhemangiomaAchromatic lensFemaleOriginal Articleuveal melanomanevusAdulttumorchoroidal hemangiomaCiliary bodymonosomy 3lymphomaStimulus (physiology)Color spaceAutoflouroscenceuvearetinoblastomaContrast SensitivityosteomaCavernous hemangiomaParvoMagnoResearch basedmedicinemelanomagene expression profilingHumansmetastasisChemotherapyChromatic scalemetastasesirisÓpticachromatic perimetryoptical coherence tomographyintravenous chemotherapybusiness.industryChoroidKonioSubtenon′s chemotherapyReproducibility of ResultsPattern recognitionGlaucomamedicine.diseaseAchromatic perimetrymagnoOphthalmologyglaucomaDiabetes Mellitus Type 2lcsh:RE1-994parvoOptometryVisual Field TestsAstrocytic hamartomavitreous seedsArtificial intelligenceprognosisVisual FieldsbusinessChromatic perimetrymalignancy
researchProduct